<DOC>
	<DOCNO>NCT00284921</DOCNO>
	<brief_summary>To prospectively evaluate de novo kidney transplant recipient , hepatitis C positive , clinical outcome immunosuppressive regimen EC-MPS free steroid comparison regimen EC-MPS standard steroid , measure hepatic function test ( ALT/AST ) 12 month treatment .</brief_summary>
	<brief_title>MYPROMS-ES02 : Safety Efficacy Basiliximab , Cyclosporine Microemulsion Enteric-coated Mycophenolate Sodium ( EC-MPS ) Versus EC-MPS Steroid Therapy Kidney Transplant Recipients Who Are Hepatitis C Positive</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion 1 . Patients hepatitis C positive ( serology test within last 12 month determine thirdgeneration assay ) . 2 . Recipients heartbeating cadaveric , live unrelated living relate nonHLA identical donor kidney transplant , treat basiliximab CsAME primary immunosuppression . Exclusion criteria 1 . Multiorgan recipient ( e.g . double kidney , kidney pancreas kidney liver ) previous transplant organ . 2 . Kidneys nonheart beat donor . 3 . ABO incompatibility donor . 4 . Patients panel reactive antibody &gt; 50 % recent assessment prior transplantation /or prior graft lose due immunological reason first six month posttransplantation patient consider increased risk acute rejection principal investigator Additional protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>kidney transplant , hepatitis C , enteric-coated mycophenolate sodium</keyword>
</DOC>